Effect of combined use of sodium hyaluronate and rhEGF on xerophthalmia in the elderly after cataract surgery

Abstract

Purpose: To determine the effect of combined use of sodium hyaluronate and recombinant human epidermal growth factor (rhEGF) on xerophthalmia in elderly patients after cataract surgery, as well as levels of serum inflammatory factors. Methods: A total of 84 elderly patients diagnosed with xerophthalmia after phacoemulsification were retrospectively studied. The patients comprised two groups: control group consisting of 40 patients given basic therapy using anti-inflammatory drugs and sodium hyaluronate eye drops (1 drop 3 times a day), and combination group (n = 44) who additionally received rhEGF. The expression levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), and tumor necrosis factor (TNF-α) in tears were determined using enzyme-linked immunosorbent assay (ELISA). After 4 weeks of treatment, clinical efficacy was assessed. Results: There was significantly higher clinical efficacy in the combination group than in the control group (p < 0.05). The values of tear break-up time (BUT) and Schirmer test (Sit) in both groups increased significantly with time, while fluorescein corneal staining (FL), symptom score, and expression levels of IL-6, hs-CRP and TNF-α significantly decreased (p < 0.05). At 2 weeks and 4 weeks of therapy, the combination group had higher values of BUT and Sit than the control group (p < 0.01). However, FL value, symptom score, and levels of IL-6, hs-CRP and TNF-α were significantly lower in the combination group than in the control group (p < 0.01). Conclusion: Sodium hyaluronate, in combination with rhEGF, improves treatment efficacy in elderly xerophthalmia patients after operation, reduces inflammatory reactions, and enhances disease alleviation. However, a multi-center prospective study will be required to validate the findings of this study.